Companies: 10,795·Total market cap: $144.5T
Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTENASDAQHealthcare
$2.68
+$0.00(+0.00%)
Market Cap$77679800
P/E Ratio
52W High$884.975
52W Low$2.6296
Overview

Aerovate Therapeutics, Inc. (AVTE) Revenue

Annual & quarterly revenue history · segment & region breakdown

AVTE · revenue · updated Jun 9, 2026

Core revenue metrics

Aerovate Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
4 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Aerovate Therapeutics, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
AVTE revenue by year · AVTE revenue history · AVTE annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Aerovate Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Aerovate Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Aerovate Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

AVTE revenue · 4 questions

AVTE's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

AVTE revenueAVTE annual revenuewhat is AVTE revenueAVTE TTM revenue

Source: FMP · Aerovate Therapeutics, Inc. SEC filings · GAAP · Aerovate Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026